Wall Street brokerages expect Axovant Sciences Ltd (NASDAQ:AXON) to report earnings of ($0.38) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Axovant Sciences’ earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.52). Axovant Sciences reported earnings of ($0.64) per share in the same quarter last year, which indicates a positive year over year growth rate of 40.6%. The company is expected to announce its next quarterly earnings report on Thursday, November 1st.
According to Zacks, analysts expect that Axovant Sciences will report full year earnings of ($1.67) per share for the current fiscal year, with EPS estimates ranging from ($2.22) to ($0.78). For the next year, analysts forecast that the company will post earnings of ($1.35) per share, with EPS estimates ranging from ($2.56) to ($0.73). Zacks’ EPS calculations are a mean average based on a survey of research analysts that cover Axovant Sciences.
Axovant Sciences (NASDAQ:AXON) last released its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.33).
In related news, Director George Bickerstaff bought 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 9th. The shares were bought at an average cost of $2.07 per share, with a total value of $51,750.00. Following the acquisition, the director now owns 50,000 shares in the company, valued at $103,500. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.00% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC raised its holdings in Axovant Sciences by 1,627.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 62,139 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 58,541 shares during the period. GSA Capital Partners LLP bought a new position in Axovant Sciences in the 2nd quarter worth $338,000. Paloma Partners Management Co bought a new position in Axovant Sciences in the 2nd quarter worth $356,000. JPMorgan Chase & Co. raised its holdings in Axovant Sciences by 2,519.0% in the 1st quarter. JPMorgan Chase & Co. now owns 183,223 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 176,227 shares during the period. Finally, A.R.T. Advisors LLC raised its holdings in Axovant Sciences by 148.9% in the 1st quarter. A.R.T. Advisors LLC now owns 416,302 shares of the biotechnology company’s stock worth $553,000 after purchasing an additional 249,074 shares during the period. 9.38% of the stock is currently owned by institutional investors.
NASDAQ AXON opened at $2.34 on Tuesday. The firm has a market cap of $308.86 million, a PE ratio of -1.14 and a beta of -0.01. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 1.48. Axovant Sciences has a 1-year low of $1.02 and a 1-year high of $6.59.
About Axovant Sciences
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.
See Also: What is a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.